Celldex Therapeutics (CLDX) Tops Q1 EPS by 3c

Celldex Therapeutics (NASDAQ: CLDX) reported Q1 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $406 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on (CLDX) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Freedom Broker Upgrades Willis Lease Finance Corp. (WLFC) to Buy
• AMC Networks (AMCX) PT Raised to $10 at UBS on Higher Cash Generation, Visibility